BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mat Nor MN, Rupenthal ID, Green CR, Acosta ML. Connexin Hemichannel Block Using Orally Delivered Tonabersat Improves Outcomes in Animal Models of Retinal Disease. Neurotherapeutics 2020;17:371-87. [PMID: 31637594 DOI: 10.1007/s13311-019-00786-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 O'Shaughnessy EM, Duffy W, Garcia-Vega L, Hussey K, Burden AD, Zamiri M, Martin PE. Dysregulation of Connexin Expression Plays a Pivotal Role in Psoriasis. Int J Mol Sci 2021;22:6060. [PMID: 34199748 DOI: 10.3390/ijms22116060] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Chen M, Rong R, Xia X. Spotlight on pyroptosis: role in pathogenesis and therapeutic potential of ocular diseases. J Neuroinflammation 2022;19:183. [PMID: 35836195 DOI: 10.1186/s12974-022-02547-2] [Reference Citation Analysis]
3 Mugisho OO, Green CR. The NLRP3 inflammasome in age-related eye disease: Evidence-based connexin hemichannel therapeutics. Exp Eye Res 2021;215:108911. [PMID: 34958779 DOI: 10.1016/j.exer.2021.108911] [Reference Citation Analysis]
4 González-Casanova J, Schmachtenberg O, Martínez AD, Sanchez HA, Harcha PA, Rojas-Gomez D. An Update on Connexin Gap Junction and Hemichannels in Diabetic Retinopathy. Int J Mol Sci 2021;22:3194. [PMID: 33801118 DOI: 10.3390/ijms22063194] [Reference Citation Analysis]
5 Acosta ML, Mat Nor MN, Guo CX, Mugisho OO, Coutinho FP, Rupenthal ID, Green CR. Connexin therapeutics: blocking connexin hemichannel pores is distinct from blocking pannexin channels or gap junctions. Neural Regen Res 2021;16:482-8. [PMID: 32985469 DOI: 10.4103/1673-5374.290097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
6 Shome A, Mugisho OO, Niederer RL, Rupenthal ID. Blocking the inflammasome: A novel approach to treat uveitis. Drug Discov Today 2021:S1359-6446(21)00306-8. [PMID: 34229084 DOI: 10.1016/j.drudis.2021.06.017] [Reference Citation Analysis]
7 Cliff CL, Williams BM, Chadjichristos CE, Mouritzen U, Squires PE, Hills CE. Connexin 43: A Target for the Treatment of Inflammation in Secondary Complications of the Kidney and Eye in Diabetes. Int J Mol Sci 2022;23:600. [PMID: 35054783 DOI: 10.3390/ijms23020600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ge K, Wang Y, Li P, Li M, Zhang W, Dan H, Hu X, Zhou J, Yang Q, Wang J, Song Z. Down-expression of the NLRP3 inflammasome delays the progression of diabetic retinopathy. Microvasc Res 2022;139:104265. [PMID: 34662588 DOI: 10.1016/j.mvr.2021.104265] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Louie HH, Shome A, Kuo CY, Rupenthal ID, Green CR, Mugisho OO. Connexin43 hemichannel block inhibits NLRP3 inflammasome activation in a human retinal explant model of diabetic retinopathy. Exp Eye Res 2021;202:108384. [PMID: 33285185 DOI: 10.1016/j.exer.2020.108384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Tittarelli A. Connexin channels modulation in pathophysiology and treatment of immune and inflammatory disorders. Biochim Biophys Acta Mol Basis Dis 2021;1867:166258. [PMID: 34450245 DOI: 10.1016/j.bbadis.2021.166258] [Reference Citation Analysis]
11 Thomas CN, Sim DA, Lee WH, Alfahad N, Dick AD, Denniston AK, Hill LJ. Emerging therapies and their delivery for treating age-related macular degeneration. Br J Pharmacol 2021. [PMID: 33769566 DOI: 10.1111/bph.15459] [Reference Citation Analysis]
12 Wan W, Zhu W, Wu Y, Long Y, Liu H, Wan W, Wan G, Yu J. Grape Seed Proanthocyanidin Extract Moderated Retinal Pigment Epithelium Cellular Senescence Through NAMPT/SIRT1/NLRP3 Pathway. J Inflamm Res 2021;14:3129-43. [PMID: 34285539 DOI: 10.2147/JIR.S306456] [Reference Citation Analysis]
13 Yang TT, Qian F, Liu L, Peng XC, Huang JR, Ren BX, Tang FR. Astroglial connexins in epileptogenesis. Seizure 2021;84:122-8. [PMID: 33348235 DOI: 10.1016/j.seizure.2020.11.022] [Reference Citation Analysis]
14 Ren J, Zhang S, Pan Y, Jin M, Li J, Luo Y, Sun X, Li G. Diabetic retinopathy: Involved cells, biomarkers, and treatments. Front Pharmacol 2022;13:953691. [DOI: 10.3389/fphar.2022.953691] [Reference Citation Analysis]
15 Garcia-Vega L, O'Shaughnessy EM, Albuloushi A, Martin PE. Connexins and the Epithelial Tissue Barrier: A Focus on Connexin 26. Biology (Basel) 2021;10:59. [PMID: 33466954 DOI: 10.3390/biology10010059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
16 Lyon H, Shome A, Rupenthal ID, Green CR, Mugisho OO. Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy. Int J Mol Sci 2020;22:E298. [PMID: 33396676 DOI: 10.3390/ijms22010298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Mat Nor MN, Rupenthal ID, Green CR, Acosta ML. Differential Action of Connexin Hemichannel and Pannexin Channel Therapeutics for Potential Treatment of Retinal Diseases. Int J Mol Sci 2021;22:1755. [PMID: 33578721 DOI: 10.3390/ijms22041755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]